SanegeneBio Secures Over $110 Million in Series B Financing Following $1.2 Billion Strategic Collaboration with Eli Lilly

12Month8Day, Focus on InnovationRNAiSANEGENEBIO, a biotech company focusing on therapy development, announces the completion of an oversubscribed financing round.1.1Billion US dollarsBThis round of financing was led by a well-known industry institution, with participation from an international sovereign fund, China Biopharmaceutical Group, Legend Capital, and others, as well as strategic investment from Eli Lilly. Existing shareholders such as Gaoling Venture Capital, Qiming Venture Partners, and Xianfeng Qiyun also continued their support.

From2021Since its establishment in [Year], SANEGENEBIO has relied on its proprietaryRNAiDrug R&D Platform, Committed to Developing First-in-Class Therapies Targeting the Liver and Extrahepatic Tissues/Best-in-classRNAiTherapy. Based on this platform, the company has built a diversified product pipeline covering different therapeutic areas such as autoimmune diseases, cardiovascular diseases, metabolic diseases, and obesity, among which multiple products have entered the clinical stage.

This round of fundraising will be used to support the company's independently developedRNAiDrug Research and Development Platform——IncludingLEAD™（Ligand and Enhancer Assisted Delivery, Novel Ligands and Synergistic Enhancer Groups for Co-delivery)Extrahepatic delivery platform to advance clinical-stage pipeline into registrational studies and accelerate the development of multiple therapeutic pipelines.

Notably, just a month ago, SANEGENEBIO had just announced its collaboration withEli LillyCompany AchievementRNAiStrategic Cooperation in Drug Development. Both parties will collaborate based on SANEGENEBIO's proprietaryLEAD™ Platform Jointly Promotes Solutions for Metabolic DiseasesRNAiDevelopment of Candidate Drugs.

LEAD™ Platform Can AchieveRNAiEfficient and specific delivery of drugs to tissues and cells outside the liver. Based on this platform, it is expected to develop a breakthrough therapy for metabolic diseases that requires only two subcutaneous injections per year. SANEGENEBIO will be responsible for...LEAD™ Platform Screens and Identifies the Best for Both Parties' Collaborative ProjectsRNAiActive molecules, Eli Lilly and Company will be responsible for the subsequent drugs.INDResearch, clinical development, and commercialization.

According to the terms of the agreement, SANEGENEBIO will receive near-term payments including an upfront payment and equity investment. In addition, SANEGENEBIO is also entitled to receive subsequent payments of up to12Hundreds of millions of dollars in development, regulatory, and sales milestone payments, as well as tiered royalties on commercial sales.

RNAiTherapy is a popular track in the current biopharmaceutical field, according to PharmaCube.NextPharma®Database, currently globally there are8PaymentRNAiDrug Approval for Marketing(Two products approved in 2025), while having super1100Multiple pipelines are under synchronous research, with the potential to further demonstrate transformative treatment for various human diseases in the future.

References:

[1]https://mp.weixin.qq.com/s/tf3RDyfZjRRNeYvPzIEBPw

[2]https://mp.weixin.qq.com/s/E-o4xUaWa9N2x0u9V683lg

PharmaCube Pro

Insights into Global Biomedical Frontiers

Empower the Transformation of China's Indigenous Innovation Achievements

Media Cooperation: 15895423126